Department of Hematology/Oncology, Transfusion and Hemapheresis Center, Kurashiki Central Hospital, Okayama, Japan.
Leuk Lymphoma. 2013 Jul;54(7):1450-8. doi: 10.3109/10428194.2012.745074. Epub 2012 Nov 26.
A study to evaluate WT1 mRNA expression levels in peripheral blood (PB) and bone marrow aspirate (BM) was conducted in 172 patients, including 115 with myelodysplastic syndromes (MDS), in Japan. The level of WT1 mRNA expression was evaluated according to the French-American-British (FAB) and World Health Organization (WHO) classifications (2001, 2008) and using the International Prognostic Scoring System and the WHO Prognostic Scoring System scales. WT1 mRNA expression levels in PB and BM were well correlated (r = 0.85), and they tended to increase with disease stage progression and in those at higher risk of leukemic transformation. WT1 mRNA expression can be a useful marker for the diagnosis and risk evaluation of MDS.
在日本，对 172 名患者（包括 115 名骨髓增生异常综合征 (MDS) 患者）进行了外周血 (PB) 和骨髓抽吸物 (BM) 中 WT1 mRNA 表达水平的研究。根据法国-美国-英国 (FAB) 和世界卫生组织 (WHO) 分类（2001 年、2008 年）以及国际预后评分系统和世界卫生组织预后评分系统量表评估 WT1 mRNA 表达水平。PB 和 BM 中的 WT1 mRNA 表达水平密切相关（r = 0.85），且随着疾病阶段的进展和向白血病转化风险较高而升高。WT1 mRNA 表达可以作为 MDS 诊断和风险评估的有用标志物。
